Hikma Pharmaceuticals on Friday confirmed that it has received several unsolicited enquiries in its Injectables business and is now undertaking a review of strategic options for its future.
In a statment the group's Chief Executive Officer said: "We have received a number of unsolicited expressions of interest in our Injectables business and will consider the best option for shareholders."
The share price rose 4.85% to 908p by 12:05.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
NR
-
Inheritance tax reforms: government urged to rethink curbs on rural reliefsMPs want the government to delay changes to inheritance rax reliefs for farmers
-
‘I’m among the thousands of millionaires leaving the UK – the new tax rules don’t make sense ’MoneyWeek spoke to a serial entrepreneur who is leaving the UK following the abolition of the non-dom tax status
